UBS upgraded the rating for GE HealthCare Technologies Inc. from Sell to Neutral on May 21, 2026 [3].
The shift reflects a recalibration of the company's valuation after a significant market correction. This move signals a change in sentiment from the investment bank as it balances the company's recent financial performance against its declining share price.
UBS lowered its price target for the NASDAQ-listed stock (GEHC) to $69, down from a previous target of $75 [2]. The bank said the approximately 30% decline [1] in the company's share price and recent performance metrics were the primary drivers for the rating change [1].
This adjustment comes as GE HealthCare navigates a complex financial landscape. In the first quarter of 2026, the company reported that sales increased 7.4% year-on-year to $5.13 billion [4]. This growth exceeded some expectations, yet the stock continued to face downward pressure.
Profitability metrics presented a more mixed picture during the same period. The company's non-GAAP profit for the first quarter of 2026 was $0.99 per share [5]. This figure was 5.7% below the consensus estimate [5].
While UBS has set a more conservative outlook with its $69 target, other market analysts maintain a higher valuation. The average one-year price target among analysts currently stands at $83 [6].
GE HealthCare continues to operate as a major player in medical technology, though the gap between reported sales growth and share price performance remains a point of scrutiny for investors. The rating flip to Neutral suggests that UBS no longer views the stock as a definitive sell, though it does not yet recommend an aggressive buy.
“UBS upgraded the rating for GE HealthCare Technologies Inc. from Sell to Neutral”
The rating upgrade to Neutral, paired with a lower price target, suggests that UBS believes the stock has already been sufficiently punished by the market. While the 30% drop in share price makes the stock more attractive than it was during the 'Sell' rating, the missed profit consensus indicates that fundamental headwinds persist despite strong top-line revenue growth.
